Leap Therapeutics Inc (LPTX) - Total Liabilities

Latest as of September 2025: $8.70 Million USD

Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has total liabilities worth $8.70 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Leap Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.

Leap Therapeutics Inc - Total Liabilities Trend (2012–2024)

This chart illustrates how Leap Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See LPTX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Leap Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Leap Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Gabelli Global Utility & Income Tr NYSE MKT:GLU	USA	$291.78K
Supergas Energy Ltd TA:SPGE	Israel	ILA913.17 Million
INNATE PHARMA SP.ADR/1 F:IDDA	Germany	€84.42 Million
Nykode Therapeutics ASA OL:NYKD	Norway	Nkr6.45 Million
Komelon Corporation KQ:049430	Korea	₩10.29 Billion
Kleannara Co Ltd KO:004545	Korea	₩466.61 Billion
KOMPLETT ASA NK -40 F:GJ60	Germany	€4.46 Billion
Micro Contact Solution Co. Ltd KQ:098120	Korea	₩15.19 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Leap Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Leap Therapeutics Inc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.21	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.23	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.76	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Leap Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Leap Therapeutics Inc (2012–2024)

The table below shows the annual total liabilities of Leap Therapeutics Inc from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	$14.08 Million	+10.97%
2023-12-31	$12.68 Million	+267.76%
2022-12-31	$3.45 Million	-65.59%
2021-12-31	$10.02 Million	+233.02%
2020-12-31	$3.01 Million	-67.27%
2019-12-31	$9.20 Million	-7.09%
2018-12-31	$9.90 Million	-44.84%
2017-12-31	$17.95 Million	+177.92%
2016-12-31	$6.46 Million	+404.85%
2015-12-31	$1.28 Million	-48.59%
2014-12-31	$2.49 Million	+26.23%
2013-12-31	$1.97 Million	-57.27%
2012-12-31	$4.61 Million	--

About Leap Therapeutics Inc

NASDAQ:LPTX USA Biotechnology

Market Cap

$116.14 Million

Market Cap Rank

#18547 Global

#4277 in USA

Share Price

$2.05

Change (1 day)

+368.57%

52-Week Range

$0.24 - $2.05

All Time High

$100.10